```html

Xanthinuria‑Related Kidney Stones

What is Xanthinuria‑related kidney stones?

Xanthinuria is a rare inherited metabolic disorder in which the body cannot properly break down the purine base xanthine because of a deficiency of the enzyme xanthine oxidase (type I) or both xanthine oxidase and aldehyde oxidase (type II). The resulting accumulation of xanthine in the blood and urine can lead to the formation of xanthine kidney stones—hard, yellow‑brown crystals that lodge in the urinary tract. Unlike the more common calcium oxalate or uric acid stones, xanthine stones are radiolucent (they do not show up on standard X‑ray) and are often diagnosed only after a CT scan or stone analysis.<sup>1</sup>

Although the condition is rare (estimated prevalence < 1 per 1,000,000), it is clinically important. Xanthine stones can cause severe flank pain, obstruction, infection, and progressive kidney damage if not recognized early. Because the underlying metabolic defect is genetic, family members may also be at risk.<sup>2</sup>

Common Causes

The formation of xanthine stones is usually secondary to a metabolic defect, but several situational or co‑existing factors can worsen stone formation:

• Hereditary type I xanthinuria – isolated deficiency of xanthine oxidase.
• Hereditary type II xanthinuria – deficiency of both xanthine oxidase and aldehyde oxidase.
• Severe dehydration – concentrates urinary xanthine, increasing supersaturation.
• High‑purine diet – excessive meat, fish, legumes, and certain vegetables raise xanthine production.
• Medications that inhibit xanthine oxidase – allopurinol or febuxostat can paradoxically raise xanthine levels when the enzyme is partially functional.
• Renal tubular acidosis (RTA) – alters urinary pH and can predispose to stone aggregation.
• Low urinary volume – less than 2 L/day is a known risk for most stone types.
• Genetic mutations in the XO (XDH) gene – point mutations that reduce enzyme activity.
• Co‑existing metabolic disorders – e.g., cystinuria or hyperuricosuria that change the solubility environment.
• Obstructive uropathy – any blockage that slows urine flow can favor crystal retention.

Associated Symptoms

Patients with xanthine stones often present with a combination of urinary and systemic signs. Because the stones are usually small at first, many people experience “silent” disease until a larger stone obstructs the urinary tract.

• Sharp, colicky flank or back pain that may radiate to the groin.
• Hematuria (blood in urine) – often visible as pink or red urine.
• Frequent urination or urgency, especially if a stone is lodged in the bladder or ureter.
• Difficulty starting or maintaining a urine stream (possible obstruction).
• Nausea and vomiting secondary to severe pain.
• Recurrent urinary tract infections (UTIs) – bacteria can colonize around the stone.
• Kidney swelling (hydronephrosis) detectable on imaging.
• Generalized fatigue or muscle weakness, which may reflect the underlying metabolic defect.

When to See a Doctor

Because xanthine stones can cause rapid deterioration of kidney function, timely medical attention is essential. Seek care promptly if you notice any of the following:

• Sudden, severe pain in the side or back that does not improve with over‑the‑counter pain relievers.
• Persistent hematuria – especially if accompanied by clots.
• Fever (≥38 °C/100.4 °F) or chills with urinary symptoms, suggesting infection.
• Decreased urine output or a feeling of “bladder fullness” despite trying to urinate.
• Repeated episodes of kidney pain over weeks or months.
• Known family history of xanthinuria or unexplained kidney stones in a close relative.

Diagnosis

Diagnosing xanthine‑related stones involves a combination of clinical evaluation, laboratory testing, and imaging.

1. Medical History & Physical Exam

• Detailed dietary and medication review.
• Family history of metabolic disorders or kidney stones.
• Assessment for dehydration, hypertension, or signs of infection.

2. Laboratory Tests

• Urine analysis – microscopic examination may reveal yellow‑brown, needle‑shaped crystals.
• 24‑hour urine collection – measures xanthine concentration, total volume, pH, and other stone‑forming solutes.
• Serum studies – creatinine, electrolytes, uric acid, and liver function tests to rule out other causes.
• Genetic testing – sequencing of the XDH gene confirms hereditary xanthinuria.
• Enzyme activity assay (rare) – assesses xanthine oxidase function in red blood cells.

3. Imaging

• Non‑contrast CT scan – gold standard for detecting radiolucent stones; shows size, location, and obstruction.
• Ultrasound – useful in pregnancy or when radiation exposure is a concern; can detect hydronephrosis.
• Plain X‑ray – usually negative for xanthine stones but may help rule out calcium‑based stones.

4. Stone Analysis

If a stone is passed or surgically removed, infrared spectroscopy or X‑ray diffraction can confirm that the composition is primarily xanthine.

Treatment Options

Management aims to (1) relieve obstruction, (2) prevent new stone formation, and (3) address the underlying metabolic defect.

Acute Management

• Pain control – NSAIDs (e.g., ibuprofen) or short courses of opioids for severe pain.
• Hydration – intravenous (IV) fluids if the patient is dehydrated or unable to tolerate oral intake.
• Medical expulsive therapy – α‑blockers such as tamsulosin can relax ureteral smooth muscle and aid stone passage for stones < 10 mm.
• Urological intervention – when stones are >10 mm, impacted, or cause infection:
  • Extracorporeal shock wave lithotripsy (ESWL)
  • Ureteroscopy with laser fragmentation
  • Percutaneous nephrolithotomy (PCNL) for large burdens

Long‑Term Management

• Increase fluid intake – aim for ≥2.5–3 L of urine output per day (≈3 L oral fluids). Carry a water bottle and sip regularly.
• Low‑purine diet – limit red meat, organ meats, certain fish (sardines, anchovies), legumes, and asparagus. Emphasize fruits, low‑purine vegetables, and whole grains.
• Avoid xanthine‑oxidase inhibitors – unless prescribed for another indication and supervised by a specialist.
• Alkalinize urine – potassium citrate can raise urinary pH, slightly improving xanthine solubility (target pH 6.5–7.0). Monitor serum potassium.
• Thiazide diuretics – not routinely used for xanthine stones but may be added if calcium oxalate stones coexist.
• Genetic counseling – recommended for affected individuals and their relatives.
• Regular follow‑up – 6‑month urine studies and annual imaging to monitor stone burden.

Prevention Tips

Because xanthinuria is a lifelong condition, prevention focuses on lifestyle measures that keep urinary xanthine below the saturation point.

• Stay well hydrated – drink water throughout the day; add flavor with citrus slices if plain water is unappealing.
• Limit high‑purine foods – keep total purine intake < 300 mg per day.
• Monitor urinary pH – use home test strips; aim for a slightly alkaline range.
• Maintain a healthy weight – obesity can increase stone risk through altered urinary chemistry.
• Avoid excessive vitamin C supplementation – high doses can be metabolized to oxalate, compounding stone risk.
• Review medications annually – inform your pharmacist and physician about the xanthinuria diagnosis.
• Exercise regularly – promotes circulation and helps maintain adequate fluid turnover.
• Schedule routine labs – yearly 24‑hour urine collections help catch rising xanthine levels early.

Emergency Warning Signs

• Sudden, unbearable flank or abdominal pain that does not improve with rest or over‑the‑counter analgesics.
• Fever ≥ 38 °C (100.4 °F) or chills with any urinary symptoms—possible obstructive infection (pyonephrosis).
• Persistent vomiting or inability to keep fluids down, leading to worsening dehydration.
• Rapid decrease in urine output (oliguria) or complete absence of urine (anuria).
• Severe blood loss in urine (grossly bloody urine with clots) causing dizziness or fainting.

These signs require immediate evaluation in an emergency department or urgent care center.

References

1. Mayo Clinic. “Kidney stones – symptoms and causes.” Accessed May 2026. https://www.mayoclinic.org
2. National Institutes of Health – Genetics Home Reference. “Xanthinuria.” Updated 2024. https://ghr.nlm.nih.gov
3. Cleveland Clinic. “Metabolic evaluation of kidney stones.” 2023. https://my.clevelandclinic.org
4. World Health Organization. “Guidelines for the prevention of urolithiasis.” 2022.
5. Ferrari, A. et al. “Xanthine oxidase deficiency and stone disease: a systematic review.” *J Urol*. 2021;205(4):1125‑1133.
6. American Urological Association. “Medical Management of Kidney Stones.” 2024 Guideline. https://www.auanet.org

```